Literature DB >> 27609596

Introduction of a PCT-based algorithm to guide antibiotic prescription in COPD exacerbation.

J Picart1, M P Moiton2, B-A Gaüzère3, V Gazaille4, X Combes5, S DiBernardo6.   

Abstract

OBJECTIVES: Prescribing antibiotics for COPD exacerbations is not easy. Procalcitonin (PCT) is a useful biomarker that helps reduce the rate of antibiotic therapies. However, its proper cut-off levels are often unknown. We aimed to assess the impact of a PCT-based algorithm to guide antibiotic therapy prescription in COPD exacerbations.
METHODS: We conducted an observational, retrospective, and before/after study. We reviewed physician practices regarding PCT test and antibiotic therapy prescription to all patients hospitalized for COPD exacerbation. We then analyzed the rate of antibiotic prescriptions and the number of PCT tests prescribed before and after the introduction of a protocol validated by previous high-power studies. The primary endpoint was the rate of antibiotic prescriptions.
RESULTS: A total of 124 patients before protocol and 121 patients after protocol were included. Antibiotic prescriptions decreased by 41% after protocol introduction (59% vs. 35%, P<0.001), with no increase in morbidity and mortality at Day 30. Compliance with protocol was complete in 60% of cases and partial (no PCT guidance to discontinue antibiotics) in 8% of cases. Both antibiotic duration (8.3 days vs. 8.7 days) and length of hospital stay (8.5 days vs. 8.3 days, P=0.78) did not change.
CONCLUSION: Hospital physicians are already using PCT-based algorithm to guide antibiotic prescription in COPD exacerbations. Disseminating information on the appropriate PCT cut-off level to use to decide whether or not to initiate antibiotics is effective. Its proper use should be clarified to reduce antibiotic prescriptions to these overexposed patients. Copyright Â
© 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antibiothérapie; Antibiotic therapy; BPCO; COPD; Exacerbation; Procalcitonin; Procalcitonine

Mesh:

Substances:

Year:  2016        PMID: 27609596     DOI: 10.1016/j.medmal.2016.07.008

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  6 in total

Review 1.  Procalcitonin: Where Are We Now?

Authors:  Bachar Hamade; David T Huang
Journal:  Crit Care Clin       Date:  2019-10-21       Impact factor: 3.598

2.  Procalcitonin-Guided Antibiotic Prescribing for Acute Exacerbations of Chronic Obstructive Pulmonary Disease in the Emergency Department.

Authors:  Leah J Nguyen; Andrew Varker; Pamela Slaughter; Daniel Boyle; Negin Nekahi
Journal:  Fed Pract       Date:  2021-06

3.  Effects of Budesonide Combined with Noninvasive Ventilation on PCT, sTREM-1, Chest Lung Compliance, Humoral Immune Function and Quality of Life in Patients with AECOPD Complicated with Type II Respiratory Failure.

Authors:  Erxiang Gao; Chi Zhang; Jianping Wang
Journal:  Open Med (Wars)       Date:  2019-03-02

4.  Introduction of Procalcitonin Testing and Antibiotic Utilization for Acute Exacerbations of Chronic Obstructive Pulmonary Disease.

Authors:  Robert J Ulrich; Daniel McClung; Bonnie R Wang; Spencer Winters; Scott A Flanders; Krishna Rao
Journal:  Infect Dis (Auckl)       Date:  2019-06-12

5.  Procalcitonin-guided antibiotic therapy for pediatrics with infective disease: A updated meta-analyses and trial sequential analysis.

Authors:  Peng Li; JiaLe Liu; Junjun Liu
Journal:  Front Cell Infect Microbiol       Date:  2022-09-21       Impact factor: 6.073

Review 6.  The Use of Serum Procalcitonin as a Diagnostic and Prognostic Biomarker in Chronic Obstructive Pulmonary Disease Exacerbations: A Literature Review Update.

Authors:  Nikolaos-Dimitrios Pantzaris; Diamantina-Xanthi Spilioti; Aikaterini Psaromyalou; Ioanna Koniari; Dimitrios Velissaris
Journal:  J Clin Med Res       Date:  2018-06-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.